Movement Alert｜TransThera Sciences Rises 5.33% in Regular Trading, Core Product Tinengotinib Phase III Trial Completes Enrollment Plus New Pipeline Approval

Market Focus07-03

On July 3, TransThera Sciences-B rose 5.33% in regular trading, trading at HK$12.52/share, with turnover of HK$84.94 million. The stock continues its upward momentum following key R&D milestones announced on July 1.

On the news front, the company released two significant updates: its core product tinengotinib completed patient enrollment for a global multi-center registrational Phase III clinical trial for advanced cholangiocarcinoma, marking a critical step toward regulatory submission. Additionally, the company received NMPA approval to initiate a Phase II clinical trial of TT-01488 tablets in combination with anti-CD20 monoclonal antibody for the treatment of mantle cell lymphoma, further expanding its hematologic oncology pipeline.

The stock has experienced extreme volatility in recent weeks after a massive unlock event on June 23 triggered a 60% single-day decline. The company subsequently announced a share buyback plan of up to RMB 100 million on June 28. Within the Biotechnology sector, BEIGENE rose 5.21%, 3SBIO rose 4.96%, and AKESO rose 4.8%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1103684444?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 09:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103684444","market":"us","top_or_hot":-1,"title":"Movement Alert｜TransThera Sciences Rises 5.33% in Regular Trading, Core Product Tinengotinib Phase III Trial Completes Enrollment Plus New Pipeline Approval","media":"Market Focus","content":"<p><p>On July 3, TransThera Sciences-B rose 5.33% in regular trading, trading at HK$12.52/share, with turnover of HK$84.94 million. The stock continues its upward momentum following key R&D milestones announced on July 1.</p><p>On the news front, the company released two significant updates: its core product tinengotinib completed patient enrollment for a global multi-center registrational Phase III clinical trial for advanced cholangiocarcinoma, marking a critical step toward regulatory submission. Additionally, the company received NMPA approval to initiate a Phase II clinical trial of TT-01488 tablets in combination with anti-CD20 monoclonal antibody for the treatment of mantle cell lymphoma, further expanding its hematologic oncology pipeline.</p><p>The stock has experienced extreme volatility in recent weeks after a massive unlock event on June 23 triggered a 60% single-day decline. The company subsequently announced a share buyback plan of up to RMB 100 million on June 28. Within the Biotechnology sector, BEIGENE rose 5.21%, 3SBIO rose 4.96%, and AKESO rose 4.8%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜TransThera Sciences Rises 5.33% in Regular Trading, Core Product Tinengotinib Phase III Trial Completes Enrollment Plus New Pipeline Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜TransThera Sciences Rises 5.33% in Regular Trading, Core Product Tinengotinib Phase III Trial Completes Enrollment Plus New Pipeline Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-03 09:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 3, TransThera Sciences-B rose 5.33% in regular trading, trading at HK$12.52/share, with turnover of HK$84.94 million. The stock continues its upward momentum following key R&D milestones announced on July 1.</p><p>On the news front, the company released two significant updates: its core product tinengotinib completed patient enrollment for a global multi-center registrational Phase III clinical trial for advanced cholangiocarcinoma, marking a critical step toward regulatory submission. Additionally, the company received NMPA approval to initiate a Phase II clinical trial of TT-01488 tablets in combination with anti-CD20 monoclonal antibody for the treatment of mantle cell lymphoma, further expanding its hematologic oncology pipeline.</p><p>The stock has experienced extreme volatility in recent weeks after a massive unlock event on June 23 triggered a 60% single-day decline. The company subsequently announced a share buyback plan of up to RMB 100 million on June 28. Within the Biotechnology sector, BEIGENE rose 5.21%, 3SBIO rose 4.96%, and AKESO rose 4.8%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02617","symbol_name":"药捷安康-B","start_time":0,"source_url":"","article_id":"1103684444","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103684444","pubTimestamp":1783043474,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 3, TransThera Sciences-B rose 5.33% in regular trading, trading at HK$12.52/share, with turnover of HK$84.94 million. The stock continues its upward momentum following key R&D milestones...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02617":"药捷安康-B"},"translate_title":"动静快讯|Tranthera Sciences常规交易涨5.33%，核心产品tinengotinib III期试验完成入组加新管线获批","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1},"content_text":"On July 3, TransThera Sciences-B rose 5.33% in regular trading, trading at HK$12.52/share, with turnover of HK$84.94 million. The stock continues its upward momentum following key R&D milestones announced on July 1.On the news front, the company released two significant updates: its core product tinengotinib completed patient enrollment for a global multi-center registrational Phase III clinical trial for advanced cholangiocarcinoma, marking a critical step toward regulatory submission. Additionally, the company received NMPA approval to initiate a Phase II clinical trial of TT-01488 tablets in combination with anti-CD20 monoclonal antibody for the treatment of mantle cell lymphoma, further expanding its hematologic oncology pipeline.The stock has experienced extreme volatility in recent weeks after a massive unlock event on June 23 triggered a 60% single-day decline. The company subsequently announced a share buyback plan of up to RMB 100 million on June 28. Within the Biotechnology sector, BEIGENE rose 5.21%, 3SBIO rose 4.96%, and AKESO rose 4.8%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1103684444","isCrawlerRequest":true}